Overview.
The 40s are when men's health risks shift from acute (injuries, infections) to chronic (cardiovascular disease, metabolic syndrome, cancer). Testosterone begins its 1-2% per year decline. Cardiovascular risk accumulates silently. Prostate cancer becomes a screening consideration. Insulin sensitivity declines. These changes are measurable years before they become symptomatic — and that gap between detectable and symptomatic is the window where prevention works best.
Ranked biomarkers.
#1 Total Testosterone
Testosterone declines approximately 1-2% per year after age 30. By 45-50, many men have levels that impair energy, muscle mass, libido, mood, and metabolic health. However, testosterone levels must be interpreted with SHBG — a man with 'normal' total testosterone but high SHBG may have functionally low free testosterone.
Optimal range: Morning draw (7-9 AM): 400-700 ng/dL (functional optimal). AUA defines hypogonadism at <300 ng/dL, but symptoms often appear at 300-400 ng/dL.
Key insight: Always test in the morning — afternoon testosterone can be 20-30% lower. Always request SHBG alongside total testosterone to calculate free testosterone. Obesity, sleep apnoea, opioids, and metabolic syndrome suppress testosterone independently of aging — treat these first before considering TRT.
#2 PSA (Prostate-Specific Antigen)
Prostate cancer is the most common cancer in men (1 in 8 lifetime risk). PSA screening detects prostate cancer at earlier, more treatable stages. Screening should begin at age 50 for average-risk men (earlier for African American men or those with family history). The decision to screen should be shared between patient and provider.
Optimal range: <4.0 ng/mL (traditional cutoff). <2.5 ng/mL for men under 60. PSA velocity (rate of change) matters as much as absolute value.
Key insight: PSA is prostate-specific, not cancer-specific. Elevated PSA can indicate benign prostatic hyperplasia (BPH), prostatitis (infection), vigorous exercise, or recent ejaculation — not just cancer. A single elevated result should always be repeated before biopsy. PSA density (PSA/prostate volume) and free:total PSA ratio improve specificity.
#3 ApoB (Apolipoprotein B)
Cardiovascular disease is the leading cause of death in men. ApoB counts all atherogenic particles — superior to LDL-C for risk prediction. Atherosclerosis begins decades before heart attacks. The 40s are the decade where cumulative exposure becomes detectable on imaging (coronary artery calcium scoring) and actionable.
Optimal range: <80 mg/dL (standard prevention). <60 mg/dL (aggressive prevention if family history or elevated Lp(a)).
Key insight: Many men with 'normal' LDL-C have discordantly high ApoB — meaning more atherogenic particles than LDL-C suggests. This is especially common with insulin resistance and metabolic syndrome (small dense LDL pattern). ApoB captures this risk; LDL-C misses it.
#4 HbA1c
Type 2 diabetes risk rises steeply in the 40s, especially with visceral adiposity. HbA1c reflects 90-day average glucose — catching the prediabetes trajectory years before fasting glucose becomes abnormal. Each 0.1% increase above 5.0% correlates with incremental cardiovascular and metabolic risk.
Optimal range: <5.3% (longevity optimal). <5.7% (standard normal). 5.7-6.4% = prediabetes. ≥6.5% = diabetes.
Key insight: Fasting glucose can appear normal while HbA1c reveals prediabetes — because glucose spikes after meals that fasting tests miss. HbA1c is the better screening test. If HbA1c is 5.5-5.6% in your 40s, you're trending toward diabetes and lifestyle intervention now prevents it.
#5 Fasting Insulin / HOMA-IR
Insulin resistance is the metabolic root of most chronic disease in men over 40 — driving cardiovascular risk, fatty liver, visceral adiposity, low testosterone (insulin reduces SHBG, increases aromatase), and cognitive decline. Fasting insulin detects it 5-10 years before HbA1c or glucose become abnormal.
Optimal range: <5 μIU/mL (optimal). HOMA-IR <2.0. Standard 'normal' fasting insulin (<25 μIU/mL) is dangerously permissive.
Key insight: Insulin resistance and low testosterone form a vicious cycle: insulin resistance increases aromatase (converting testosterone to estradiol), which suppresses LH/FSH, which further lowers testosterone. Breaking the cycle with exercise and weight loss improves both simultaneously — often more effectively than TRT alone.
#6 hs-CRP
Chronic low-grade inflammation drives atherosclerosis, insulin resistance, and cancer risk. hs-CRP integrates inflammatory signals from visceral fat, poor sleep, gut dysfunction, and subclinical infections. In men over 40, hs-CRP >2.0 mg/L nearly doubles cardiovascular risk independent of cholesterol.
Optimal range: <1.0 mg/L (optimal). <3.0 mg/L (standard 'low risk'). >3.0 mg/L warrants investigation and lifestyle intervention.
Key insight: Elevated hs-CRP in a man over 40 should trigger assessment of: visceral adiposity (waist circumference), sleep quality (apnoea screening if snoring), dental health (periodontitis), and diet quality — not just cardiac risk scoring.
#7 Vitamin D (25-OH)
Vitamin D supports testosterone production, bone density (osteoporosis is underdiagnosed in men), muscle strength, and immune function. Deficiency is present in ~40% of adult men. Low vitamin D is associated with lower testosterone in observational studies, though supplementation evidence for raising testosterone is mixed.
Optimal range: 40-60 ng/mL. Standard 'sufficient' (>30 ng/mL) may not be optimal for musculoskeletal and hormonal health.
Key insight: Male osteoporosis is a silent epidemic — 1 in 4 men over 50 will have an osteoporotic fracture. Vitamin D + weight-bearing exercise is the foundation of bone health. Don't assume osteoporosis is only a women's problem.
#8 TSH
Thyroid dysfunction in men is less common than women but still affects 3-5% over age 40. Hypothyroidism causes fatigue, weight gain, depression, and elevated cholesterol — symptoms easily attributed to 'just aging'. Hyperthyroidism causes anxiety, weight loss, and atrial fibrillation.
Optimal range: 0.5-2.5 mIU/L (functional optimal). Standard range extends to 4.5 mIU/L.
Key insight: In men, hypothyroidism is more commonly missed because doctors screen women more aggressively. If you have unexplained fatigue, weight gain, or elevated cholesterol despite good diet, request TSH. It's a simple, inexpensive test that catches a highly treatable condition.
#9 Ferritin
Unlike women (who lose iron monthly through menstruation), men accumulate iron throughout life. Elevated ferritin (>300 ng/mL) in men is associated with cardiovascular disease, diabetes, liver dysfunction, and haemochromatosis (genetic iron overload — affects 1 in 200 Northern Europeans).
Optimal range: 40-150 ng/mL (optimal range for men). >300 ng/mL warrants investigation. Check transferrin saturation if ferritin is elevated.
Key insight: Haemochromatosis is the most common genetic disease in people of Northern European descent. It's diagnosed by elevated ferritin + transferrin saturation >45%. If caught early, treatment is simply blood donation. Undiagnosed, it causes cirrhosis, diabetes, cardiomyopathy, and joint disease — all preventable.
#10 eGFR / Creatinine
Chronic kidney disease affects ~15% of adults and is more common in men. eGFR naturally declines with age (~1 mL/min/year after 40), but pathological decline from hypertension, diabetes, or NSAID use can accelerate this. Silent CKD increases cardiovascular risk and affects medication dosing.
Optimal range: eGFR >90 mL/min (normal). 60-89 = mild decline (may be age-appropriate). <60 sustained for 3+ months = CKD. Calculate from routine creatinine.
Key insight: Long-term NSAID use (ibuprofen, naproxen) is a common cause of accelerated kidney decline in men — especially with pre-existing hypertension or dehydration during exercise. If you regularly use NSAIDs, your eGFR should be monitored annually.
How to test.
Request an annual fasting morning blood draw (7-9 AM): CBC, CMP (includes creatinine/eGFR), lipid panel with ApoB, total testosterone + SHBG, PSA (after shared decision-making), TSH, fasting insulin + glucose, HbA1c, hs-CRP, vitamin D, ferritin. One draw covers everything. Track trends year over year.
FAQs.
When should I start getting PSA tested?
Shared decision-making with your doctor starting at age 50 (or 40-45 if African American or family history of prostate cancer). PSA screening reduces prostate cancer death but carries risks of overdiagnosis. Discuss your individual risk factors and preferences with your provider.
My testosterone is 350 ng/dL — is that low?
It's borderline. AUA defines hypogonadism at <300 ng/dL, but many men experience symptoms at 300-400 ng/dL. Context matters: was it a morning draw? What's your SHBG? Do you have symptoms? Obesity, sleep apnoea, and metabolic syndrome suppress testosterone and should be addressed before considering TRT.
Should I worry about iron overload?
If your ferritin is >300 ng/mL, yes — check transferrin saturation. Haemochromatosis (genetic iron overload) affects 1 in 200 Northern Europeans and is easily treatable if caught early (regular blood donation). Undiagnosed, it causes liver cirrhosis, diabetes, and heart failure by age 50-60.
How is this different from the women-over-40 panel?
Men add: testosterone + SHBG (age-related decline), PSA (prostate screening), and focus on iron excess (not deficiency). Women add: FSH/estradiol (perimenopause), bone density markers (accelerated loss), and focus on iron deficiency (menstrual losses). Cardiovascular, metabolic, and thyroid markers are equally important for both.
Verdict.
The 40s are when men's chronic disease risk becomes detectable — and preventable. These 10 biomarkers cover the major dimensions: hormonal health (testosterone), cancer screening (PSA), cardiovascular risk (ApoB, hs-CRP), metabolic health (insulin, HbA1c), thyroid function (TSH), bone and muscle support (vitamin D), iron balance (ferritin), and kidney function (eGFR). An annual panel catches problems in the window where intervention works — not after the heart attack, the diabetes diagnosis, or the advanced prostate cancer.